Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies

被引:2
|
作者
Fujisawa, Takuo [1 ]
Tsuta, Koji [2 ]
Yanagimoto, Hiroaki [3 ]
Yagi, Masao [1 ]
Suzuki, Kensuke [1 ]
Nishikawa, Kenji [4 ]
Takahashi, Masaru [4 ]
Okada, Hisatake [4 ]
Nakano, Yasushi [4 ]
Iwai, Hiroshi [1 ]
机构
[1] Kansai Med Univ, Dept Otolaryngol Head & Neck Surg, Osaka 5731010, Japan
[2] Kansai Med Univ, Dept Pathol & Lab Med, Osaka 5731010, Japan
[3] Kansai Med Univ, Dept Surg, Osaka 5731010, Japan
[4] Kon Minolta Inc, Corp R&D Headquarters, Bio Adv Technol Div, Bio Syst Dev Grp, Tokyo 1918511, Japan
关键词
programmed death ligand-1; digital immunostaining; ELISA; nCounter; EXPRESSION; PEMBROLIZUMAB;
D O I
10.3892/mco.2019.1801
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualization. Our previously developed digital immunostaining technique is highly sensitive and quantitative with the ability to quantify particles that bind in a one-to-one fashion with antibody in each cell. Determining the differences in the titer of each antibody with digital immunostaining may be beneficial for future harmonized analysis. To demonstrate the accuracy of digital immunostaining, the present study compared the number of particles with ELISA and nCounter data from five cell lines. NCI-H460 exhib-ited the highest level of PD-L1 protein, followed by A549, PC-3, NCI-H1299, and NCI-H446 cells. In addition, the PD-L1 mRNA values determined by nCounter corresponded with the order of the protein levels determined by ELISA. The present study revealed that digital immunostaining for PD-L1 was highly associated with ELISA and nCounter data. Among the four antibodies tested, the titer of all but SP142 coincided with ELISA and nCounter data. These results indicated that our digital immunostaining technique may be beneficial for future harmonized analysis.
引用
收藏
页码:391 / 396
页数:6
相关论文
共 50 条
  • [21] Comparing the performance of three PD-L1 antibodies for PD-L1 expression in renal cell carcinoma
    Park, S.
    Wi, Y. C.
    Shin, S.
    Jang, K.
    VIRCHOWS ARCHIV, 2019, 475 : S181 - S182
  • [22] Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Sun, Woo Young
    Lee, Yu Kyung
    Koo, Ja Seung
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [23] Immunohistochemical assessment of the PD-1/PD-L1 axis in follicular lymphoma
    Szumera-Cieckiewicz, A.
    Sokol, K.
    Rymkiewicz, G.
    Jastrzebska, A.
    Paszkiewicz-Kozik, E.
    Kotarska, M.
    Walewski, J.
    Prochorec-Sobieszek, M.
    VIRCHOWS ARCHIV, 2018, 473 : S97 - S98
  • [24] Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Kim, H. -M.
    Sun, W. -Y.
    Lee, Y. -K.
    Koo, J. -S.
    VIRCHOWS ARCHIV, 2016, 469 : S55 - S55
  • [25] Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
    Woo Young Sun
    Yu Kyung Lee
    Ja Seung Koo
    Journal of Translational Medicine, 14
  • [26] Molecular interactions of antibodies with PD-1/PD-L1 proteins
    Vasilakaki, Sofia
    Vathiotis, Ioannis
    Panagiotou, Emmanouil
    Dimakakos, Evangelos
    Gomatou, Georgia
    Kotteas, Elias
    IMMUNOTHERAPY, 2024, 16 (01) : 21 - 28
  • [27] Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
    Chen, Miaomiao
    Zhou, Yuli
    Bao, Kaicheng
    Chen, Siyu
    Song, Guoqing
    Wang, Siliang
    BIODRUGS, 2025,
  • [28] Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
    Katsuya, Yuki
    Fujita, Yu
    Horinouchi, Hidehito
    Ohe, Yuichiro
    Watanabe, Shun-ichi
    Tsuta, Koji
    LUNG CANCER, 2015, 88 (02) : 154 - 159
  • [29] A cell based bioluminescent reporter assay for rapid measuring function of PD-1 or PD-L1 therapeutic antibodies
    Cong, Mei
    Karassina, Natasha
    Cheng, Jey
    Fan, Frank
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Novel PD-1 blockade bioassay to assess therapeutic antibodies in PD-1 and PD-L1 immunotherapy programs
    Cheng, Zhi-Jie Jey
    Karassina, Natasha
    Grailer, Jamison
    Hartnett, Jim
    Fan, Frank
    Cong, Mei
    CANCER RESEARCH, 2015, 75